<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95042">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867580</url>
  </required_header>
  <id_info>
    <org_study_id>AHS.2011.ULTA.04</org_study_id>
    <nct_id>NCT01867580</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds</brief_title>
  <official_title>A Prospective, Randomized, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KCI USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effectiveness of the V.A.C.Ulta Negative
      Pressure Wound Therapy System and V.A.C. VeraFlo Dressing System in wounds that require
      operative debridement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Operative Debridements</measure>
    <time_frame>until the wound is deemed ready for closure or coverage by the investigator up to 64 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Wounds and Injuries</condition>
  <arm_group>
    <arm_group_label>V.A.C.Ulta with instillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V.A.C.Ulta without instillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>V.A.C.Ulta with instillation</intervention_name>
    <description>NPWT with instillation of a wound cleanser</description>
    <arm_group_label>V.A.C.Ulta with instillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>V.A.C.Ulta without instillation</intervention_name>
    <description>NPWT only</description>
    <arm_group_label>V.A.C.Ulta without instillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The Subject:

          -  has a wound prior to informed consent

          -  will be admitted as an inpatient

          -  is &gt;= 18 years of age at time of consent

          -  is able to provide his/her own informed consent

          -  is willing and able to return for all scheduled and required study visits

          -  has an open wound &gt;= 4cm in any plane of measurement excluding tunnels after initial
             surgical debridement

          -  has a wound that is appropriate for NPWT according to approved indications for use

          -  has not participated in a clinical trial within the past 30 days

          -  has a 30 day wound history available if the wound has been previously treated

        Exclusion Criteria:

        The Subject:

          -  is pregnant as determined by a positive serum or urine pregnancy test at the time of
             screening

          -  has a life expectancy of &lt; 12 months

          -  is not healthy enough to undergo surgery for any reason

          -  has, in the investigator's opinion, any clinically significant condition that would
             impair the participant's ability to comply with the study procedures

          -  has, in the opinion of the investigator, a condition that will not allow the subject
             to tolerate the therapy (e.g. painful conditions such as vasculitis)

          -  has rheumatoid arthritis

          -  has a bleeding disorder or coagulopathy

          -  has a wound that contains antibiotic cement or beads

          -  has an ischemic lower extremity wound as determined by lack of detectable pulses in
             the extremity or ankle-brachial pressure indices of &lt; 0.9 with a history of diabetes,
             or &lt; 0.6 if the subject is non-diabetic

          -  has a known allergy or hypersensitivity to V.A.C. Therapy dressing components
             including polyurethane or polyvinyl alcohol (drape and foam), or materials that
             contain acrylic adhesive (drape adhesive)

          -  has a known allergy or hyper sensitivity to 3M Cavilon No Sting Barrier Film or any
             of its components including Hexamethyldisiloxane, isooctane, acrylate terpolymer,
             polyphenylmethysiloxane, copolymer

          -  has a know allergy or hypersensitivity to Prontosan or any of its components
             including polyhexamethylene biguanide (PHMB), or undecylenamidopropyl betaine

          -  has received NPWT on the study wound within the last 30 days

          -  has a wound that is contraindicated with Prontosan

             a. presence of hyaline cartilage in the wound

          -  has a wound that is contraindicated with V.A.C. Therapy including:

               1. malignancy in the wound

               2. untreated osteomyelitis

               3. non-enteric or unexplored fistulas

               4. necrotic tissue with eschar remaining in the wound after debridement (NOTE: Once
                  necrotic tissue or eschar is removed from the wound bed, subjects may be
                  included)

               5. unprotected, exposed blood vessels, anastomotic sites, organs, or nerves in
                  direct contact with foam

          -  use of intervening layers between the wound bed and foam

          -  has a wound that is contraindicated with V.A.C. VeraFlo Therapy including:

               1. Thoracic or abdominal cavities

               2. Unexplored wounds that may communicate with adjacent body cavities

          -  has a wound that is closed after the initial debridement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
